GlassScriptPhysician profile
Evan R Minkoff
NPI 1831150739
$3,203.40
in general payments reported to CMS, 2019-2025
32 companies · $743 in 2025
The $743 reported for 2025 was more than what 89% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
See the full distribution for Sports Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $195 · 2021: $326 · 2022: $326 · 2023: $756 · 2024: $520 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,319.81 | 2019-2025 | Belbuca |
| Scilex Pharmaceuticals INC. | $219.80 | 2022-2025 | Ztlido |
| Forte Bio-Pharma LLC | $203.27 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.83 | 2022-2025 | Relistor |
| Virtus Pharmaceuticals LLC | $148.12 | 2021-2025 | Levorphanol Tartrate |
| Valinor Pharma, LLC | $133.30 | 2023-2025 | Movantik |
| Boston Scientific Corporation | $130.49 | 2020-2023 | Wavewriter Alpha Prime 16 |
| Vertex Pharmaceuticals Incorporated | $76.06 | 2024-2025 | |
| Sentynl Therapeutics, INC. | $73.33 | 2019-2020 | |
| Almatica Pharma LLC | $69.75 | 2022-2023 | Gralise |
| Grt US Holding, INC. | $63.09 | 2022 | |
| Nevro Corp. | $56.88 | 2019-2020 | |
| Abbott Laboratories | $55.01 | 2023-2024 | Proclaim, Eterna |
| Fidia Pharma USA INC. | $49.64 | 2019-2020 | |
| Averitas Pharma INC. | $48.42 | 2023 | Qutenza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $42.64 | 2022 | |
| Medtronic, INC. | $37.64 | 2024 | Synchromedii |
| Daiichi Sankyo INC. | $35.74 | 2019 | |
| Redhill Biopharma INC. | $34.41 | 2020 | |
| Horizon Therapeutics Plc | $28.95 | 2020 | |
| Avanos Medical | $24.30 | 2019 | |
| Bioventus LLC | $21.83 | 2021 | |
| Lilly USA, LLC | $21.15 | 2021 | |
| Hikma Pharmaceuticals USA | $18.63 | 2022 | |
| Ibsa Pharma INC. | $18.22 | 2023 | Tirosint, Licart |
| Alnylam Pharmaceuticals INC. | $17.39 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.39 | 2023 | Seglentis |
| Si-Bone, INC. | $17.33 | 2019 | |
| Medtronic USA, INC. | $17.30 | 2019 | |
| Stratus Medical, LLC | $13.70 | 2022 | |
| Vertos Medical, INC. | $12.07 | 2022 | |
| Abbvie INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Minkoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.